Citations

Showing 10 of 108083 citations.

Challenges in Choosing a Medication for Type 2 Diabetes
Rodríguez‐Gutiérrez, René , Salcido‐Montenegro, Alejandro , Elizondo-Plazas, Anasofía , González‐González, José Gerardo , González-González, José Gerardo

Mayo Clinic

Diabetes Technology & Therapeutics | September 26, 2017 | Volume: 19 | Issue: 10 | Pages: 557-559

10.1089/dia.2017.0166 | PMID 28949772 Get It

Patient Outcomes from Lung Cancer and Diabetes Mellitus: A Matched Case–Control Study
Karlin, Nina J. , Amin, Shailja B , Buras, Matthew , Verona, Patricia M , Cook, Curtiss B. , Buras, Matthew R , Kosiorek, Heidi

Mayo Clinic

Future Science OA | September 26, 2017 | Volume: 4 | Issue: 1 | Pages: No page available

10.4155/fsoa-2017-0081 | PMID 29255620 Get It

A Review of Immune Checkpoint Inhibitors for the Management of Locally Advanced or Metastatic Urothelial Carcinoma
Hanna, Kirollos S.

Mayo Clinic

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | September 26, 2017 | Volume: 37 | Issue: 11 | Pages: 1391-1405

10.1002/phar.2033 | PMID 28950037 Get It

Urothelial carcinoma ( UC ) is the second most common malignancy of the genitourinary system and the sixth most common cancer in the United States. The overall incidence of UC appears to be on the decline, but death rates have remained stable. Stage IV metastatic disease is associated with only a 5% survival rate at 5 years. Gemcitabine and cisplatin combinations or dose‐dense methotrexate, vinblastine, doxorubicin, and cisplatin are the preferred regimens for individuals with advance, metastatic disease and a good performance status and organ function. Second‐line therapies in this setting are limited. During the course of 1 year, five immune checkpoint inhibitors were approved for treatment of cancers in the locally advanced or metastatic setting: atezolizumab, nivolumab, durvalumab, avelumab, and pembrolizumab. Immunotherapies have played a significant role in the treatment of various cancers and have continued to expand. It is of utmost importance that practitioners include checkpoint inhibitors as treatment options for UC . Based on the limited data, pembrolizumab and atezolizumab may be the drugs of choice, as they are supported by the most influential data to date; however, further research is warranted. Ongoing clinical trials will further assess the benefits of inducing cellular immunity in the treatment of UC . These therapies mark a new landscape in the treatment of UC . In this article, the available data on immune checkpoint inhibitors for the treatment of locally advanced or metastatic UC and their place in therapy are reviewed.
A Case Series of the Probability Density and Cumulative Distribution of Laryngeal Disease in a Tertiary Care Voice Center
Fuente, Jaime de la , Garrett, C. Gaelyn , Ossoff, Robert H., Vinson, Kim, Francis, David O. , Gelbard, Alexander , de la Fuente, Jaime, Gelbard, Alexander , Vinson, Kimberly N.

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | September 26, 2017 | Volume: 126 | Issue: 11 | Pages: 748-754

10.1177/0003489417728945 | PMID 28949246 Get It

Objective: To examine the distribution of clinic and operative pathology in a tertiary care laryngology practice. Methods: Probability density and cumulative distribution analyses (Pareto analysis) was used to rank order laryngeal conditions seen in an outpatient tertiary care laryngology practice and those requiring surgical intervention during a 3-year period. Results: Among 3783 new clinic consultations and 1380 operative procedures, voice disorders were the most common primary diagnostic category seen in clinic (n = 3223), followed by airway (n = 374) and swallowing (n = 186) disorders. Within the voice strata, the most common primary ICD-9 code used was dysphonia (41%), followed by unilateral vocal fold paralysis (UVFP) (9%) and cough (7%). Among new voice patients, 45% were found to have a structural abnormality. The most common surgical indications were laryngotracheal stenosis (37%), followed by recurrent respiratory papillomatosis (18%) and UVFP (17%). Conclusions: Nearly 55% of patients presenting to a tertiary referral laryngology practice did not have an identifiable structural abnormality in the larynx on direct or indirect examination. The distribution of ICD-9 codes requiring surgical intervention was disparate from that seen in clinic. Application of the Pareto principle may improve resource allocation in laryngology, but these initial results require confirmation across multiple institutions.
Regional analysis and genetic association of nigrostriatal degeneration in Lewy body disease
Kasanuki, Koji , Diehl, Nancy N. , Murray, Melissa E. , Koga, Shunsuke , Soto, Alexandra I., Ross, Owen A. , Dickson, Dennis W. , Koga, Shunsuke , Soto, Alexandra, Dickson, Dennis W , Ross, Owen A , Murray, Melissa E , Heckman, Michael G.

Mayo Clinic

Movement Disorders | September 26, 2017 | Volume: 32 | Issue: 11 | Pages: 1584-1593

10.1002/mds.27184 | PMID 28949048 Get It

ABSTRACTBackgroundA number of genetic loci are associated with risk for Parkinson's disease (PD) based on genome‐wide association studies; however, the relationship between genetic variants and nigrostriatal degeneration, which is the structural correlate of parkinsonism, has not been reported.ObjectivesWe quantified nigrostriatal dopaminergic integrity with image analysis of putaminal tyrosine hydroxylase immunoreactivity in 492 brains with Lewy body disease and used this pathologic endophenotype to explore possible association with PD genetic variants.MethodsThe study cases had Lewy‐related pathology and variable degrees of nigrostriatal degeneration. They were assigned to one of the following clinical subgroups according to their predominant clinical syndrome: parkinsonism‐predominant, parkinsonism+dementia, and dementia‐predominant. In addition to putaminal tyrosine hydroxylase immunoreactivity, semiquantitative scoring was used to assess substantia nigra neuronal loss. A total of 29 PD genetic risk variants were genotyped on each case.ResultsWhen compared with controls, tyrosine hydroxylase immunoreactivity was reduced in Lewy body cases in the dorsolateral (79%) and ventromedial (57%) putamen. The dorsolateral region was better preserved in dementia‐predominant cases than in cases with parkinsonism. Dorsolateral putaminal tyrosine hydroxylase immunoreactivity correlated with neuronal loss in the ventrolateral substantia nigra. Genetic analyses showed no significant association of PD risk variants with putaminal tyrosine hydroxylase immunoreactivity.ConclusionsThe results confirm regional differences in putaminal dopaminergic degeneration and vulnerability of nigrostriatal pathway in Lewy body disorders with parkinsonism. The lack of association with PD genetic risk variants suggests that they may not be associated with quantitative endophenotypes of nigrostriatal degeneration, but more likely related to the risk of disease per se. © 2017 International Parkinson and Movement Disorder Society
Resting and Exercise Haemodynamics in Relation to Six-Minute Walk Test in Patients with Heart Failure and Preserved Ejection Fraction
Wolsk, Emil , Kaye, David M. , Borlaug, Barry A. , Kitzman, Dalane W. , Komtebedde, Jan , Ponikowski, Piotr , Shah, Sanjiv J. , Gustafsson, Finn , Borlaug, Barry A , Kaye, David M , Shah, Sanjiv J , Burkhoff, Daniel , Lam, Carolyn S.P. , Ponikowski, Piotr , Gustafsson, Finn

Mayo Clinic

European Journal of Heart Failure | September 26, 2017 | Volume: 20 | Issue: 4 | Pages: 715-722

10.1002/ejhf.976 | PMID 28949052 Get It

Abstract Aims Patients with heart failure and preserved ejection fraction (HFpEF) are characterized by functional impairment and an abnormal haemodynamic response to exercise. The six-minute walk test (6MWT) serves as a standardized test for functional capacity quantification in heart failure patients, and is associated with cardiovascular outcomes. However, as the association between 6MWT and haemodynamic parameters during rest and exercise in HFpEF patients is unknown, we sought to elucidate this relationship. Methods and results Overall, 64 patients enrolled in the REDUCE LAP-HF trial completed a 6MWT at baseline. Univariate and multivariable linear regression models were used to assess the associations between 6MWT and measured or derived haemodynamic variables at baseline, during light/moderate exercise (20 W), and at peak supine exercise. The average 6MWT distance was 318 ± 106 m. At rest, in a multivariable model, only pulmonary capillary wedge pressure (PCWP) was significantly associated with 6MWT [coefficient: –5.4, 95% confidence interval (CI) –10.4, –0.5, P = 0.033]. During light/moderate exercise, mean pulmonary artery pressure was associated with 6MWT in a multivariable model (coefficient: –3.5, 95% CI –6.8, –0.3, P = 0.033). During peak exercise, central venous pressure, cardiac index (CI), and PCWP/CI correlated with 6MWT; however, workload corrected PCWP was the only variable independently associated with 6MWT (coefficient: –0.8, 95% CI –1.3, –0.4, P < 0.001). The variance in 6MWT was modestly explained by measured or derived haemodynamic variables at rest or at any stage of exercise (r2 = 7–17%). Conclusion Workload corrected PCWP correlated best with 6MWT performance in HFpEF patients. Baseline haemodynamic variables were modestly correlated with 6MWT, suggesting that 6MWT performance in HFpEF patients may be significantly influenced by extra-cardiac factors.
Autosomal recessive inheritance of ADCY5 -related generalized dystonia and myoclonus
Barrett, Matthew J. , Williams, Eli S. , Chambers, Chelsea , Dhamija, Radhika , Barrett, Matthew J , Dhamija, Radhika

Mayo Clinic

Neurology Genetics | September 26, 2017 | Volume: 3 | Issue: 5 | Pages: No page available

10.1212/nxg.0000000000000193 | PMID 28971144 Get It

Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer
Doostan, Iman , Karakaş, Cansu , Kohansal, Mehrnoosh, Low, Kwang-Hui, Moulder, Stacy , Keyomarsi, Khandan , Ellis, Matthew J. , Olson, John A. , Suman, Vera J. , Hunt, Kelly K.

Mayo Clinic

Clinical Cancer Research | September 25, 2017 | Volume: 23 | Issue: 23 | Pages: 7288-7300

10.1158/1078-0432.ccr-17-1544 | PMID 28947566 Get It

Abstract Purpose: Preoperative aromatase inhibitor (AI) therapy has demonstrated efficacy in hormone receptor (HR)-positive postmenopausal breast cancer. However, many patients have disease that is either intrinsically resistant to AIs or that responds initially but develops resistance after prolonged exposure. We have shown that patients with breast tumors expressing the deregulated forms of cyclin E [low molecular weight forms (LMW-E)] have poor overall survival. Herein, we hypothesize that LMW-E expression can identify HR-positive tumors that are unresponsive to neoadjuvant AI therapy due to the inability of AIs to induce a cytostatic effect. Experimental Design: LMW-E was examined in breast cancer specimens from 58 patients enrolled in the American College of Surgeons Oncology Group Z1031, a neoadjuvant AI clinical trial. The mechanisms of LMW-E–mediated resistance to AI were evaluated in vitro and in vivo using an inducible model system of cyclin E (full-length and LMW-E) in aromatase-overexpressing MCF7 cells. Results: Breast cancer recurrence-free interval was significantly worse in patients with LMW-E–positive tumors who received AI neoadjuvant therapy, compared with those with LMW-E negative tumors. Upon LMW-E induction, MCF7 xenografts were unresponsive to letrozole in vivo, resulting in increased tumor volume after treatment with AIs. LMW-E expression overcame cell-cycle inhibition by AIs in a CDK2/Rb-dependent manner, and inhibition of CDK2 by dinaciclib reversed LMW-E–mediated resistance, whereas treatment with palbociclib, a CDK4/6 inhibitor, did not. Conclusions: Collectively, these findings suggest that cell-cycle deregulation by LMW-E mediates resistance to AIs and a combination of CDK2 inhibitors and AIs may be an effective treatment in patients with HR-positive tumors that express LMW-E. Clin Cancer Res; 23(23); 7288–300. ©2017 AACR.
Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma
Kizilbash, Sani H. , Kawashima, Ryo, Parrish, Karen E. , Carlson, Brett L. , Mladek, Ann C. , Decker, Paul A. , Kitange, Gaspar J. , Shen, Yuqiao , Feng, Ying , Protter, Andrew A., Elmquist, William F. , Gupta, Shiv K. , Chang, Kenneth , Bakken, Katrina K. , Schroeder, Mark A. , Kizilbash, Sani H , Chang, Kenneth Tou En , Decker, Paul A. , Sarkaria, Jann N. , Mladek, Ann C

Mayo Clinic

Molecular Cancer Therapeutics | September 25, 2017 | Volume: 16 | Issue: 12 | Pages: 2735-2746

10.1158/1535-7163.mct-17-0365 | PMID 28947502 Get It

Abstract Poly ADP-ribose polymerase (PARP) inhibitors, including talazoparib, potentiate temozolomide efficacy in multiple tumor types; however, talazoparib-mediated sensitization has not been evaluated in orthotopic glioblastoma (GBM) models. This study evaluates talazoparib ± temozolomide in clinically relevant GBM models. Talazoparib at 1–3 nmol/L sensitized T98G, U251, and GBM12 cells to temozolomide, and enhanced DNA damage signaling and G2–M arrest in vitro. In vivo cyclical therapy with talazoparib (0.15 mg/kg twice daily) combined with low-dose temozolomide (5 mg/kg daily) was well tolerated. This talazoparib/temozolomide regimen prolonged tumor stasis more than temozolomide alone in heterotopic GBM12 xenografts [median time to endpoint: 76 days versus 50 days temozolomide (P = 0.005), 11 days placebo (P < 0.001)]. However, talazoparib/temozolomide did not accentuate survival beyond that of temozolomide alone in corresponding orthotopic xenografts [median survival 37 vs. 30 days with temozolomide (P = 0.93), 14 days with placebo, P < 0.001]. Average brain and plasma talazoparib concentrations at 2 hours after a single dose (0.15 mg/kg) were 0.49 ± 0.07 ng/g and 25.5±4.1 ng/mL, respectively. The brain/plasma distribution of talazoparib in Bcrp−/− versus wild-type (WT) mice did not differ, whereas the brain/plasma ratio in Mdr1a/b−/− mice was higher than WT mice (0.23 vs. 0.02, P < 0.001). Consistent with the in vivo brain distribution, overexpression of MDR1 decreased talazoparib accumulation in MDCKII cells. These results indicate that talazoparib has significant MDR1 efflux liability that may restrict delivery across the blood–brain barrier, and this may explain the loss of talazoparib-mediated temozolomide sensitization in orthotopic versus heterotopic GBM xenografts. Mol Cancer Ther; 16(12); 2735–46. ©2017 AACR.
Comprehensive Characterization of Alternative Polyadenylation in Human Cancer
Xiang, Yu , Ye, Youqiong , Lou, Yanyan , Zhang, Zhao , Chen, Ning-Yuan, Kim, Yoon-Jin , Ozguc, Fatma Muge, Diao, Lixia , Xia, Yang, Kellems, Rodney E. , Shyu, Ann‐Bin, Mills, Gordon B. , Han, Leng , Ye, Youqiong , Han, Leng , Mills, Gordon B , Yang, Yang , Cai, Chunyan C. , Mills, Tingting , Chen, Ning‐Yuan, Karmouty‐Quintana, Harry , Xia, Yang, Chen, Zheng , Blackburn, Michael R. , Yoo, Seung Hee

Mayo Clinic

JNCI: Journal of the National Cancer Institute | September 25, 2017 | Volume: 110 | Issue: 4 | Pages: 379-389

10.1093/jnci/djx223 | PMID 29106591 Get It